Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)
China · Delayed Price · Currency is CNY 32.72
+2.58 (8.56%)
Feb 4, 2026, 3:04 PM CST
SHE:300683 Revenue
Wuhan Hiteck Biological Pharma Co.,Ltd had revenue of 146.84M CNY in the quarter ending September 30, 2025, a decrease of -11.74%. This brings the company's revenue in the last twelve months to 619.88M, up 0.82% year-over-year. In the year 2024, Wuhan Hiteck Biological Pharma Co.,Ltd had annual revenue of 648.97M with 7.75% growth.
Revenue (ttm)
619.88M
Revenue Growth
+0.82%
P/S Ratio
6.36
Revenue / Employee
473.55K
Employees
1,309
Market Cap
3.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 648.97M | 46.69M | 7.75% |
| Dec 31, 2023 | 602.28M | -86.34M | -12.54% |
| Jan 1, 2023 | 688.63M | 73.94M | 12.03% |
| Jan 1, 2022 | 614.68M | 90.56M | 17.28% |
| Dec 31, 2020 | 524.12M | -96.04M | -15.49% |
| Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Henan Taloph Pharmaceutical Stock Co.,Ltd | 1.79B |
| PKU HealthCare Corp.,Ltd. | 1.76B |
| Nanjing Well Pharmaceutical Group | 1.31B |
| Huaren Pharmaceutical | 1.26B |
| Shaanxi Panlong Pharmaceutical Group Limited By Share | 1.10B |
| Zhejiang Shengda Bio-Pharm | 839.82M |
| Shandong Wohua Pharmaceutical | 816.95M |
| Qianjiang Yongan Pharmaceutical | 797.25M |